Actualización clínica en niños y adolescentes | 10 ABR 23

Linfoma de Burkitt

El linfoma de Burkitt es un linfoma de células B muy agresivo y el cáncer humano de proliferación más rápida.
Autor/a: Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson N Engl J Med 2022;387:1111-22.
INDICE:  1. Texto principal | 2. Referencia bibliográfica
Referencia bibliográfica

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443-59.

2. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-20.

3. Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and non coding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 2019; 133: 1313-24.

4. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 2013; 369: 1915-25.

5. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma. J Clin Oncol 2020; 38: 2519- 29.

6. Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021; 137: 374-86.

7. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46: 218-23.

8. O’Conor GT, Davies JN. Malignant tumors in African children: with special reference to malignant lymphoma. J Pediatr 1960; 56: 526-35.

9. Burkitt D. A children’s cancer dependent on climatic factors. Nature 1962; 194: 232-4.

10. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964; 1: 702-3.

11. Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 1967; 157: 1064-5.

12. Manolov G, Manolova Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 1972; 237: 33-4.

13. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79: 7824-7.

14. Kafuko GW, Burkitt DP. Burkitt’s lymphoma and malaria. Int J Cancer 1970; 6: 1-9.

15. Robbiani DF, Bothmer A, Callen E, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008; 135: 1028-38.

16. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. rev., Vol. 2. Lyon, France: IARC, 2017.

17. Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood 2018; 132: 254-63.

18. de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 1978; 274: 756-61.

19. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer 2010; 126: 1732-9.

20. Ziegler JL, Drew WL, Miner RC, et al. Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet 1982; 2: 631-3.

21. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23: 4430-8.

22. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006; 354: 2431-42.

23. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-30.

24. Wagener R, Bens S, Toprak UH, et al. Cryptic insertion of MYC exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of “MYC-negative” Burkitt lymphoma. Haematologica 2020; 105(4): e202-e205.

25. Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, et al. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 2019; 104: 1822-9.

26. Wagener R, Seufert J, Raimondi F, et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019; 133: 962-6.

27. López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun 2019; 10: 1459.

28. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88: 5413-7.

29. Reutter K, Sandmann S, Rohde J, et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia 2021; 35: 639-43.

30. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-34.

31. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-34.

32. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002; 416: 648-53.

33. Gong C, Krupka JA, Gao J, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell 2021; 81(19): 4059-4075.e11.

34. Nascimento EM, Cox CL, MacArthur S, et al. The opposing transcriptional functions of Sin3a and c-Myc are required to maintain tissue homeostasis. Nat Cell Biol 2011; 13: 1395-405.

35. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44: 1316-20.

36. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-5.

37. Giulino-Roth L, Wang K, MacDonald TY, et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012; 120: 5181-4.

38. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood 2019; 134: 1598-607.

39. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989; 56: 777-83.

40. Kabrani E, Chu VT, Tasouri E, et al. Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells. Blood 2018; 132: 2670-83.

41. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024